Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV

被引：26

作者：

Brueckl, Wolfgang M. ^{[1
]}

Reck, Martin ^{[2
]}

Rittmeyer, Achim ^{[3
]}

Kollmeier, Jens ^{[4
]}

Wesseler, Claas ^{[5
]}

Wiest, Gunther H. ^{[5
]}

Christopoulos, Petros ^{[6
]}

Tufman, Amanda ^{[7
]}

Hoffknecht, Petra ^{[8
]}

Ulm, Bernhard ^{[9
]}

Reich, Fabian ^{[1
]}

Ficker, Joachim H. ^{[1
]}

Laack, Eckart ^{[10
]}

机构：

[1] Paracelsus Med Univ, Nuremberg Lung Canc Ctr, Dept Resp Med Allergol & Sleep Med, Gen Hosp Nuremberg, Ernst Nathan Str 1, D-90419 Nurnberg, Germany

[2] LungenClin Grosshansdorf, Grosshansdorf, Germany

[3] Lungenfachklin Immenhausen, Ambulanz Pneumol Onkol, Kassel, Germany

[4] Helios Klinikum Emil von Behring, Lungenklin Heckeshom, Berlin, Germany

[5] Asklepios Klinikum Harburg, Asklepios Tumorzentrum Hamburg, Hamburg, Germany

[6] Thoraxklin Heidelberg gGmbH, Thoraxonkol, Heidelberg, Germany

[7] Klinikum Univ Munchen, Med Klin & Poliklin Pneumol 5, Munich, Germany

[8] Zentrum Klin Thoraxonkol Franziskus Hosp Harderbe, Georgsmarienhutte, Germany

[9] Unabhangige Stat Beratung Bemhard Ulm, Munich, Germany

[10] Praxis, Hamatoonkol Hamburg, Hamburg, Germany

来源：

CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2020年 / 14卷

关键词：

Lung cancer; palliative treatment; angiogenesis inhibitor; ramucirumab; immune checkpoint inhibitor; OPEN-LABEL; RESPONSE RATES; CHEMOTHERAPY; MULTICENTER; MICROENVIRONMENT; ATEZOLIZUMAB; COMBINATION; NIVOLUMAB; PLACEBO; PHASE-3;

D O I：

10.1177/1179554920951358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects with chemotherapy. Effects might be even stronger after immune-checkpoint-inhibitor (ICI) therapy. The purpose of this analysis was to evaluate the efficacy of ramucirumab plus docetaxel (R + D) as third-line treatment after failure of a first-line platinum-based chemotherapy and a second-line ICI treatment in patients with non-small-cell lung cancer (NSCLC) stage IV. METHODS: Retrospective data were collected from 9 German thoracic oncology centers. Only patients who had received at least 1 cycle of third-line R + D were included. The numbers of cycles, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were investigated. RESULTS: Sixty-seven patients met the criteria for inclusion. Third-line treatment with R + D achieved an ORR of 36% and a disease control rate (DCR) of 69%. Median PFS for third-line therapy was 6.8 months with a duration of response (DOR) of 10.2 months. A median OS of 29 months was observed from the start of first-line therapy with a median OS of 11.0 months from the start of third-line treatment. No unexpected toxicities occurred. CONCLUSION: R + D is a highly effective and safe third-line treatment after failure of second-line programmed cell death protein 1/programmed cell death-ligand 1 (PD1/PD-L1)-derived ICI therapy irrespective of NSCLC histology. As there may be synergistic effects of second- and third-line treatments, this sequence is a very suitable option for patients not treated with first-line ICI. In addition, R + D should continue to be investigated as a second-line treatment option after failure of chemotherapy plus ICI in the palliative first-line treatment.

引用

页数：9

共 33 条

[1]

[Anonymous], 2019, ANN ONCOL S5

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[4] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[5] Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program [J].

Corral, J. ;

Majem, M. ;

Rodriguez-Abreu, D. ;

Carcereny, E. ;

Cortes, A. A. ;

Llorente, M. ;

Lopez Picazo, J. M. ;

Garcia, Y. ;

Domine, M. ;

Lopez Criado, M. P. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (09) :1270-1279

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial [J].

Fehrenbacher, Louis ;

Spira, Alexander ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

Vansteenkiste, Johan ;

Mazieres, Julien ;

Park, Keunchil ;

Smith, David ;

Artal-Cortes, Angel ;

Lewanski, Conrad ;

Braiteh, Fadi ;

Waterkamp, Daniel ;

He, Pei ;

Zou, Wei ;

Chen, Daniel S. ;

Yi, Jing ;

Sandler, Alan ;

Rittmeyer, Achim .

LANCET, 2016, 387 (10030) :1837-1846

[8] Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization [J].

Fukumura, Dai ;

Jain, Rakesh K. .

MICROVASCULAR RESEARCH, 2007, 74 (2-3) :72-84

[9] Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo [J].

Gabrilovich, D ;

Ishida, T ;

Oyama, T ;

Ran, S ;

Kravtsov, V ;

Nadaf, S ;

Carbone, DP .

BLOOD, 1998, 92 (11) :4150-4166

[10] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

← 1 2 3 4 →